Receptor tyrosine kinases as therapeutic targets in rhabdomyosarcoma.

Journal Article (Journal Article)

Rhabdomyosarcomas (RMSs) are the most common soft tissue sarcomas of childhood and adolescence. To date, there are no effective treatments that target the genetic abnormalities in RMS, and current treatment options for high-risk groups are not adequate. Over the past two decades, research into the molecular mechanisms of RMS has identified key genes and signaling pathways involved in disease pathogenesis. In these studies, members of the receptor tyrosine kinase (RTK) family of cell surface receptors have been characterized as druggable targets for RMS. Through small molecule inhibitors, ligand-neutralizing agents, and monoclonal receptor-blocking antibodies, RTK activity can be manipulated to block oncogenic properties associated with RMS. Herein, we review the members of the RTK family that are implicated in RMS tumorigenesis and discuss both the problems and promise of targeting RTKs in RMS.

Full Text

Duke Authors

Cited Authors

  • Crose, LES; Linardic, CM

Published Date

  • 2011

Published In

Volume / Issue

  • 2011 /

Start / End Page

  • 756982 -

PubMed ID

  • 21253475

Pubmed Central ID

  • PMC3022188

Electronic International Standard Serial Number (EISSN)

  • 1369-1643

Digital Object Identifier (DOI)

  • 10.1155/2011/756982


  • eng

Conference Location

  • Egypt